Smallpox: a potential agent of bioterrorism.

[1]  D. Relman,et al.  Smallpox Research Activities: U.S. Interagency Collaboration, 2001 , 2002, Emerging infectious diseases.

[2]  D. Smee,et al.  Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug. , 2002, Antiviral research.

[3]  K. Hostetler,et al.  Enhanced Inhibition of Orthopoxvirus Replication In Vitro by Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir , 2002, Antimicrobial Agents and Chemotherapy.

[4]  J. D. Millar,et al.  Modeling potential responses to smallpox as a bioterrorist weapon. , 2001, Emerging infectious diseases.

[5]  D. Smee,et al.  Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. , 2001, Antiviral research.

[6]  E. De Clercq,et al.  A case of human Orf in an immunocompromised patient treated successfully with cidofovir cream , 2001, Journal of medical virology.

[7]  D. Smee,et al.  Treatment of Lethal Vaccinia Virus Respiratory Infections in Mice with Cidofovir , 2001, Antiviral chemistry & chemotherapy.

[8]  E. De Clercq,et al.  Efficacy of 2-Amino-7-(1,3-Dihydroxy-2-Propoxymethyl)Purine for Treatment of Vaccinia Virus (Orthopoxvirus) Infections in Mice , 2001, Antimicrobial Agents and Chemotherapy.

[9]  M. Turner,et al.  Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. , 2000, Archives of dermatology.

[10]  J. Blanco,et al.  Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. , 2000, Acta dermato-venereologica.

[11]  C. Cockerell,et al.  TOPICAL CIDOFOVIR FOR MOLLUSCUM CONTAGIOSUM IN CHILDREN , 1999, Pediatric dermatology.

[12]  A. Thrasher,et al.  Topical cidofovir for severe molluscum contagiosum , 1999, The Lancet.

[13]  Philip K. Russell,et al.  Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 1999, JAMA.

[14]  S. Tyring,et al.  Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. , 1997, Archives of dermatology.

[15]  F. Ennis,et al.  Immunologic responses to vaccinia vaccines administered by different parenteral routes. , 1997, The Journal of infectious diseases.

[16]  B. Kuppermann,et al.  Intravenous Cidofovir for Peripheral Cytomegalovirus Retinitis in Patients with AIDS , 1997, Annals of Internal Medicine.

[17]  J. Neyts,et al.  Efficacy of (S)‐1‐(3‐hydroxy‐2‐phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice , 1993, Journal of medical virology.

[18]  T. Schwartz,et al.  The persistence of neutralizing antibodies after revaccination against smallpox. , 1990, The Journal of infectious diseases.

[19]  T. S. Jones,et al.  Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. , 1987, The New England journal of medicine.

[20]  A. Hall,et al.  The Global Eradication of Smallpox. Final Report of the Global Commission for the Certification of Smallpox Eradication , 1982 .

[21]  Koplan Jp,et al.  Smallpox vaccination reactions, prophylaxis, and therapy of complications. , 1975 .

[22]  J. Sharp,et al.  Experience of anti-vaccinia immunoglobulin in the United Kingdom. , 1973, Lancet.

[23]  T. Mack,et al.  Smallpox in Europe, 1950-1971. , 1972, The Journal of infectious diseases.

[24]  D. Thomas,et al.  Epidemiology of smallpox in West Pakistan. II. Determinants of intravillage spread other than acquired immunity. , 1972, American journal of epidemiology.

[25]  D. Thomas,et al.  Epidemiology of smallpox in West Pakistan. I. Acquired immunity and the distribution of disease. , 1972, American journal of epidemiology.

[26]  J D Millar,et al.  Complications of smallpox vaccination, 1968. , 1969, The New England journal of medicine.

[27]  C. Kempe.  Studies on Smallpox and Complications of Smallpox Vaccination. E. Mead Johnson Award Address. , 1960 .

[28]  C. Dixon.  Smallpox in Tripolitania, 1946: an epidemiological and clinical study of 500 cases, including trials of penicillin treatment , 1948, Epidemiology and Infection.

[29]  D. Smee,et al.  Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. , 2000, The Journal of infectious diseases.

[30]  C. Roth,et al.  Human monkeypox -- Kasai Oriental, Democratic Republic of Congo, February 1996-October 1997. , 1997, MMWR. Morbidity and mortality weekly report.

[31]  福見 秀雄.  The vaccination : theory and practice , 1975 .